Arcturus Therape Stock Price, News & Analysis

Arcturus (Nasdaq: ARCT) reported interim Phase 2 results for inhaled mRNA therapy ARCT-032 in Class I cystic fibrosis patients.

In a 28-day, 10 mg cohort (6 adults) the treatment was generally safe and well tolerated; one SAE occurred well after dosing that a Data Monitoring Committee found no convincing evidence of product relatedness. AI-enhanced HRCT showed mucus plug and mucus volume reductions in 4 of 6 participants (largest mucus volume drop −67.4%). A post hoc exploratory analysis showed average ppFEV1 +3.8% absolute (+5.1% relative) in 4 of 6 participants vs pre-treatment baseline. A 12-week safety and preliminary efficacy study enrolling up to 20 participants is planned for H1 2026; an ongoing 15 mg cohort is enrolling to evaluate dose response.

Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in liver and respiratory rare disease therapeutics and infectious disease vaccines, has announced its participation in four upcoming investor conferences in September 2025.

The company will participate in fireside chats at Citi's Biopharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), and Cantor Global Healthcare Conference (Sept 5). Additionally, Arcturus will deliver a presentation at the H.C. Wainwright Global Investment Conference (Sept 9).

Arcturus Therapeutics (NASDAQ:ARCT) reported Q2 2025 financial results and pipeline updates. Key highlights include: Q2 revenue of $28.3M (down from $49.9M in Q2 2024) and net loss of $9.2M ($0.34 per share). The company maintains a strong cash position of $253.4M, extending runway into 2028.

Pipeline progress includes: Cystic fibrosis (ARCT-032) Phase 2 interim data from nine participants expected September 2025; OTC deficiency (ARCT-810) showed positive Phase 2 results with Phase 3 planning in H1 2026; KOSTAIVE® regulatory submissions advancing globally; and Seasonal flu vaccine (ARCT-2138) demonstrated positive Phase 1 results in both young and older adults.

Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has scheduled its second quarter 2025 financial results announcement. The company will release its Q2 results on Monday, August 11, 2025, after market close.

A conference call and webcast will follow at 4:30 PM Eastern Time the same day. Investors can access the call via domestic (1-800-274-8461) or international (1-203-518-9814) numbers using the conference ID "ARCTURUS".

Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has announced its participation in two upcoming investor conferences.

The company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29, 2025, at 12:40 p.m. ET, and deliver a presentation at the CG 45th Annual Growth Conference on August 12, 2025, at 8:30 a.m. ET.

Arcturus Therapeutics (NASDAQ: ARCT) has announced a virtual Key Opinion Leader (KOL) presentation scheduled for June 30, 2025, at 12:00 p.m. ET to discuss interim data from Phase 2 trials of ARCT-810 for Ornithine Transcarbamylase (OTC) deficiency. The presentation will feature two prominent experts: Dr. Marshall Summar, CEO at Uncommon Cures and a renowned expert in urea cycle disorders with over 40 years of experience, and Dr. Johannes Häberle, Director at the University of Zurich's Metabolic Laboratory. The event will focus on safety and pharmacodynamics data from multiple doses of ARCT-810 in adolescent and adult OTC deficiency patients. A press release with the data summary will be issued at 11 am ET before the presentation.

Arcturus Therapeutics (Nasdaq: ARCT), a commercial mRNA medicine company specializing in infectious disease vaccines and liver and respiratory rare diseases, has announced its participation in two upcoming investor conferences in June 2025:

- Jefferies Global Healthcare Conference: Presentation scheduled for Wednesday, June 4, 2025, at 4:20 p.m. ET

- Goldman Sachs Annual Global Healthcare Conference: Fireside Chat scheduled for Monday, June 9, 2025, at 3:20 p.m. ET

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 2025 financial results and pipeline updates. The company has prioritized its mRNA therapeutics pipeline, extending cash runway into 2028. Key developments include: Financial Highlights: - Q1 2025 revenues: $29.4M (vs $38.0M in Q1 2024) - Net loss: $14.1M or ($0.52) per share - Cash position: $273.8M as of March 31, 2025 Pipeline Progress: - ARCT-032 (CF): Phase 2 interim data expected mid-2025, enrollment completion by year-end - ARCT-810 (OTC): Phase 2 interim data expected Q2 2025 - ARCT-2304: Received FDA Fast Track Designation for H5N1 flu vaccine - KOSTAIVE® (COVID-19 vaccine): Received EU approval milestone payment from CSL; UK MAA filing expected Q2 2025, US BLA filing in Q3 2025